Two Sigma Advisers LP Sells 137,300 Shares of Humana Inc. (NYSE:HUM)

Two Sigma Advisers LP cut its position in shares of Humana Inc. (NYSE:HUM) by 13.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 906,280 shares of the insurance provider’s stock after selling 137,300 shares during the period. Two Sigma Advisers LP owned about 0.75% of Humana worth $229,932,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. FPC Investment Advisory Inc. bought a new stake in shares of Humana during the fourth quarter valued at approximately $27,000. Centricity Wealth Management LLC bought a new stake in Humana in the fourth quarter valued at $30,000. LFA Lugano Financial Advisors SA grew its position in Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the period. OFI Invest Asset Management bought a new stake in Humana in the fourth quarter valued at $33,000. Finally, Transce3nd LLC bought a new stake in Humana in the fourth quarter valued at $38,000. 92.38% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on HUM shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Raymond James upgraded Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price target on the stock in a research report on Thursday, May 1st. StockNews.com upgraded Humana from a “hold” rating to a “buy” rating in a research report on Friday, May 9th. Morgan Stanley lowered their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Finally, Mizuho boosted their price objective on Humana from $305.00 to $316.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 9th. Seventeen analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Humana presently has a consensus rating of “Hold” and a consensus price target of $286.81.

Humana Trading Up 4.4%

Shares of HUM opened at $237.42 on Monday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 12-month low of $212.45 and a 12-month high of $406.46. The firm has a market capitalization of $28.65 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49. The stock’s fifty day simple moving average is $262.94 and its 200-day simple moving average is $269.57.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 11.70% and a net margin of 1.02%. The business had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. During the same quarter in the prior year, the firm posted $7.23 earnings per share. The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. As a group, research analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a yield of 1.49%. Humana’s dividend payout ratio is presently 25.04%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.